Chinese formulation, TCM actives, and the market outrunning its reputation.
You can probably name a dozen Korean brands and not one Chinese one. That is a gap in Western editorial coverage, not a gap in the market — and China's largest beauty company is arriving in 400 Ulta stores.
The rule is narrower than the brands imply and wider than the campaigners concede — which makes it the clearest case study going in how a claim can be true, outdated and misleading at once.
Ten new ingredients cleared in the decade to 2014. Ninety cleared in 2024 alone. That is the structural reason C-beauty formulation got interesting — and it beats any story about consumer nationalism.
The gap finally narrowed in June 2026 — and the first filter through the door had been legal in China for about two decades, at a higher concentration than the US just permitted.
In three years, China's share of Korea's cosmetics exports fell from roughly two-thirds to under a quarter. The products did not get worse. The assumption behind them collapsed.
The tradition produced a Nobel Prize, so blanket dismissal is not available. Neither is blanket acceptance — and the best human trial on ginseng and wrinkles tested a pill, not a cream.
Picking one skin state and selling through hospital dermatology departments is a genuinely smart strategy. Whether the house botanical earns its billing is a separate question, and the answer is not the one either side wants.
The standard product post opens with a percentage rather than a lifestyle photo, and the regulator makes brands publish their evidence. Both of those are ahead of the West. The metric they created is the problem.